Drug Manufacturers - General
Compare Stocks
5 / 10Stock Comparison
SRXH vs TDOC vs AMWL vs OPRX vs DOCS
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Information Services
Medical - Healthcare Information Services
Medical - Healthcare Information Services
Medical - Healthcare Information Services
SRXH vs TDOC vs AMWL vs OPRX vs DOCS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Drug Manufacturers - General | Medical - Healthcare Information Services | Medical - Healthcare Information Services | Medical - Healthcare Information Services | Medical - Healthcare Information Services |
| Market Cap | $1M | $1.26B | $129M | $124M | $5.24B |
| Revenue (TTM) | $119M | $2.51B | $182M | $109M | $638M |
| Net Income (TTM) | $-11M | $-171M | $-88M | $5M | $239M |
| Gross Margin | 19.9% | 65.6% | 38.7% | 67.3% | 89.7% |
| Operating Margin | -4.9% | -7.6% | -50.6% | 10.7% | 37.4% |
| Forward P/E | — | — | — | 7.0x | 16.8x |
| Total Debt | $39M | $1.04B | $5M | $5M | $12M |
| Cash & Equiv. | $2M | $781M | $182M | $23M | $210M |
SRXH vs TDOC vs AMWL vs OPRX vs DOCS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 25 | May 26 | Return |
|---|---|---|---|
| SRx Health Solution… (SRXH) | 100 | 5.8 | -94.2% |
| Teladoc Health, Inc. (TDOC) | 100 | 96.8 | -3.2% |
| American Well Corpo… (AMWL) | 100 | 105.7 | +5.7% |
| OptimizeRx Corporat… (OPRX) | 100 | 72.7 | -27.3% |
| Doximity, Inc. (DOCS) | 100 | 45.8 | -54.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SRXH vs TDOC vs AMWL vs OPRX vs DOCS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SRXH is the #2 pick in this set and the best alternative if growth is your priority.
- 28.4% revenue growth vs AMWL's -2.0%
Among these 5 stocks, TDOC doesn't own a clear edge in any measured category.
AMWL ranks third and is worth considering specifically for momentum.
- +14.3% vs SRXH's -84.6%
OPRX is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 18.8%, EPS growth 124.5%, 3Y rev CAGR 20.6%
- 110.5% 10Y total return vs DOCS's -50.9%
- Lower P/E (7.0x vs 16.8x)
DOCS carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 1.03
- Lower volatility, beta 1.03, Low D/E 1.1%, current ratio 6.97x
- Beta 1.03, current ratio 6.97x
- 37.5% margin vs AMWL's -48.2%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 28.4% revenue growth vs AMWL's -2.0% | |
| Value | Lower P/E (7.0x vs 16.8x) | |
| Quality / Margins | 37.5% margin vs AMWL's -48.2% | |
| Stability / Safety | Beta 1.03 vs OPRX's 2.28, lower leverage | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +14.3% vs SRXH's -84.6% | |
| Efficiency (ROA) | 20.7% ROA vs AMWL's -25.1%, ROIC 20.0% vs -95.1% |
SRXH vs TDOC vs AMWL vs OPRX vs DOCS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
SRXH vs TDOC vs AMWL vs OPRX vs DOCS — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
DOCS leads in 3 of 6 categories
SRXH leads 0 • TDOC leads 0 • AMWL leads 0 • OPRX leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
DOCS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TDOC is the larger business by revenue, generating $2.5B annually — 23.0x OPRX's $109M. DOCS is the more profitable business, keeping 37.5% of every revenue dollar as net income compared to AMWL's -48.2%. On growth, DOCS holds the edge at +9.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $119M | $2.5B | $182M | $109M | $638M |
| EBITDAEarnings before interest/tax | — | $42M | -$59M | $16M | $250M |
| Net IncomeAfter-tax profit | — | -$171M | -$88M | $5M | $239M |
| Free Cash FlowCash after capex | — | $251M | -$42M | $12M | $314M |
| Gross MarginGross profit ÷ Revenue | +19.9% | +65.6% | +38.7% | +67.3% | +89.7% |
| Operating MarginEBIT ÷ Revenue | -4.9% | -7.6% | -50.6% | +10.7% | +37.4% |
| Net MarginNet income ÷ Revenue | -9.4% | -6.8% | -48.2% | +4.7% | +37.5% |
| FCF MarginFCF ÷ Revenue | +1.3% | +10.0% | -22.9% | +10.6% | +49.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -2.5% | -100.0% | -0.2% | +9.8% |
| EPS Growth (YoY)Latest quarter vs prior year | — | +32.1% | +44.5% | — | -16.2% |
Valuation Metrics
Evenly matched — SRXH and OPRX each lead in 2 of 6 comparable metrics.
Valuation Metrics
At 23.5x trailing earnings, DOCS trades at a 5% valuation discount to OPRX's 24.6x P/E. On an enterprise value basis, OPRX's 6.5x EV/EBITDA is more attractive than DOCS's 21.1x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1M | $1.3B | $129M | $124M | $5.2B |
| Enterprise ValueMkt cap + debt − cash | $29M | $1.5B | -$48M | $105M | $5.0B |
| Trailing P/EPrice ÷ TTM EPS | -0.17x | -6.11x | -1.30x | 24.56x | 23.45x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 7.04x | 16.83x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 0.30x |
| EV / EBITDAEnterprise value multiple | — | 15.13x | — | 6.55x | 21.14x |
| Price / SalesMarket cap ÷ Revenue | 0.02x | 0.50x | 0.52x | 1.13x | 9.18x |
| Price / BookPrice ÷ Book value/share | — | 0.89x | 0.50x | 0.98x | 4.84x |
| Price / FCFMarket cap ÷ FCF | 1.20x | 4.40x | — | 6.62x | 19.64x |
Profitability & Efficiency
DOCS leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
DOCS delivers a 24.4% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-33 for AMWL. DOCS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to TDOC's 0.75x. On the Piotroski fundamental quality scale (0–9), DOCS scores 9/9 vs SRXH's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | — | -12.4% | -33.5% | +4.2% | +24.4% |
| ROA (TTM)Return on assets | -22.4% | -5.9% | -25.1% | +3.0% | +20.7% |
| ROICReturn on invested capital | -18.1% | -11.5% | -95.1% | +7.1% | +20.0% |
| ROCEReturn on capital employed | -98.8% | -10.0% | -36.6% | +7.6% | +22.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 | 6 | 8 | 9 |
| Debt / EquityFinancial leverage | — | 0.75x | 0.02x | 0.04x | 0.01x |
| Net DebtTotal debt minus cash | $37M | $259M | -$178M | -$19M | -$197M |
| Cash & Equiv.Liquid assets | $2M | $781M | $182M | $23M | $210M |
| Total DebtShort + long-term debt | $39M | $1.0B | $5M | $5M | $12M |
| Interest CoverageEBIT ÷ Interest expense | -2.83x | -8.76x | -239.18x | 1.26x | — |
Total Returns (Dividends Reinvested)
DOCS leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DOCS five years ago would be worth $4,911 today (with dividends reinvested), compared to $278 for AMWL. Over the past 12 months, AMWL leads with a +14.3% total return vs SRXH's -84.6%. The 3-year compound annual growth rate (CAGR) favors DOCS at -8.8% vs SRXH's -62.3% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -52.9% | -1.3% | +59.8% | -46.6% | -39.9% |
| 1-Year ReturnPast 12 months | -84.6% | +1.5% | +14.3% | -30.1% | -55.4% |
| 3-Year ReturnCumulative with dividends | -94.6% | -73.3% | -80.7% | -54.4% | -24.2% |
| 5-Year ReturnCumulative with dividends | -94.6% | -95.4% | -97.2% | -87.3% | -50.9% |
| 10-Year ReturnCumulative with dividends | -94.6% | -41.1% | -98.3% | +110.5% | -50.9% |
| CAGR (3Y)Annualised 3-year return | -62.3% | -35.6% | -42.2% | -23.0% | -8.8% |
Risk & Volatility
Evenly matched — SRXH and AMWL each lead in 1 of 2 comparable metrics.
Risk & Volatility
SRXH is the less volatile stock with a -0.32 beta — it tends to amplify market swings less than OPRX's 2.28 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMWL currently trades 84.7% from its 52-week high vs SRXH's 9.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.32x | 1.91x | 1.47x | 2.28x | 1.03x |
| 52-Week HighHighest price in past year | $1.25 | $9.77 | $9.15 | $22.25 | $76.51 |
| 52-Week LowLowest price in past year | $0.08 | $4.40 | $3.71 | $5.54 | $20.55 |
| % of 52W HighCurrent price vs 52-week peak | +9.0% | +71.2% | +84.7% | +29.8% | +34.0% |
| RSI (14)Momentum oscillator 0–100 | 41.4 | 74.1 | 67.1 | 46.9 | 60.1 |
| Avg Volume (50D)Average daily shares traded | 22.0M | 5.5M | 59K | 476K | 2.7M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: TDOC as "Hold", OPRX as "Buy", DOCS as "Buy". Consensus price targets imply 156.4% upside for OPRX (target: $17) vs 8.9% for TDOC (target: $8).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | — | Buy | Buy |
| Price TargetConsensus 12-month target | — | $7.58 | — | $17.00 | $42.79 |
| # AnalystsCovering analysts | — | 42 | — | 15 | 22 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | 1 | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.0% | 0.0% | +2.3% |
DOCS leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
SRXH vs TDOC vs AMWL vs OPRX vs DOCS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SRXH or TDOC or AMWL or OPRX or DOCS a better buy right now?
For growth investors, SRx Health Solutions Inc.
(SRXH) is the stronger pick with 28. 4% revenue growth year-over-year, versus -2. 0% for American Well Corporation (AMWL). Doximity, Inc. (DOCS) offers the better valuation at 23. 5x trailing P/E (16. 8x forward), making it the more compelling value choice. Analysts rate OptimizeRx Corporation (OPRX) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SRXH or TDOC or AMWL or OPRX or DOCS?
On trailing P/E, Doximity, Inc.
(DOCS) is the cheapest at 23. 5x versus OptimizeRx Corporation at 24. 6x. On forward P/E, OptimizeRx Corporation is actually cheaper at 7. 0x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — SRXH or TDOC or AMWL or OPRX or DOCS?
Over the past 5 years, Doximity, Inc.
(DOCS) delivered a total return of -50. 9%, compared to -97. 2% for American Well Corporation (AMWL). Over 10 years, the gap is even starker: OPRX returned +110. 5% versus AMWL's -98. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SRXH or TDOC or AMWL or OPRX or DOCS?
By beta (market sensitivity over 5 years), SRx Health Solutions Inc.
(SRXH) is the lower-risk stock at -0. 32β versus OptimizeRx Corporation's 2. 28β — meaning OPRX is approximately -805% more volatile than SRXH relative to the S&P 500. On balance sheet safety, Doximity, Inc. (DOCS) carries a lower debt/equity ratio of 1% versus 75% for Teladoc Health, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — SRXH or TDOC or AMWL or OPRX or DOCS?
By revenue growth (latest reported year), SRx Health Solutions Inc.
(SRXH) is pulling ahead at 28. 4% versus -2. 0% for American Well Corporation (AMWL). On earnings-per-share growth, the picture is similar: OptimizeRx Corporation grew EPS 124. 5% year-over-year, compared to 54. 2% for Doximity, Inc.. Over a 3-year CAGR, OPRX leads at 20. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SRXH or TDOC or AMWL or OPRX or DOCS?
Doximity, Inc.
(DOCS) is the more profitable company, earning 39. 1% net margin versus -38. 4% for American Well Corporation — meaning it keeps 39. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 39. 9% versus -42. 2% for AMWL. At the gross margin level — before operating expenses — DOCS leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SRXH or TDOC or AMWL or OPRX or DOCS more undervalued right now?
On forward earnings alone, OptimizeRx Corporation (OPRX) trades at 7.
0x forward P/E versus 16. 8x for Doximity, Inc. — 9. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPRX: 156. 4% to $17. 00.
08Which pays a better dividend — SRXH or TDOC or AMWL or OPRX or DOCS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is SRXH or TDOC or AMWL or OPRX or DOCS better for a retirement portfolio?
For long-horizon retirement investors, SRx Health Solutions Inc.
(SRXH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 32)). Teladoc Health, Inc. (TDOC) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SRXH: -94. 6%, TDOC: -41. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SRXH and TDOC and AMWL and OPRX and DOCS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SRXH is a small-cap high-growth stock; TDOC is a small-cap quality compounder stock; AMWL is a small-cap quality compounder stock; OPRX is a small-cap high-growth stock; DOCS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.